Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3

Published on February 7, 2022

Immunovant's (IMVT) earnings miss estimates in fiscal third-quarter, which ended on Dec 31, 2021. Focus remains on lead pipeline candidate batoclimab.

Continue reading on website
Other news

Sanofi's (SNY) Enjaymo Gets FDA Nod For Rare Blood Disorder

February 7, 2022
The FDA approves Sanofi's (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.

Neil Young Says Spotify CEO, Not Joe Rogan, is the 'Big Problem': A Complete Timeline Of the Spotify and Joe Rogan Controversy

February 7, 2022
The streaming giant is facing massive backlash amid several controversies that have sparked around its lightning-rod podcaster.